Rx to OTC Switches 2009

    Published: May 1, 2009 | Price: $995.00 – $7,000.00

    While many areas of the pharmaceutical industry will suffer from current economic conditions worldwide, sales of over the counter drugs are widely anticipated to grow as consumers seek cheaper alternatives. Manufacturers are expected to switch prescription drugs to over the counter status where possible. In the early part of this decade there was a delcine in Rx to switches, since 2006 there has been a number of uses of this tactic to extend revenue of pharmaceutical products. In Kalorama Information's...
    Pharmaceutical Markets in India

    Published: April 1, 2009 | Price: $995.00 – $2,590.00

    The pharmaceutical market in India ranks among the top twenty markets in the world with the potential to move up in ranking rather quickly. This market will be essential for pharmaceutical companies exploring new opportunities for growth. Developing regions will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. This report Pharmaceutical Market in India provides market watchers with needed information on this growing market, including:   Market Size and Forecast...
    Pharmaceutical Markets in Russia

    Published: January 1, 2009 | Price: $995.00 – $1,990.00

    The pharmaceutical market in Russia ranks among the top twenty markets in the world with the potential to move up in ranking rather quickly. This market will be one of several that major pharmaceutical companies are exploring for new opportunities for growth. Reliance on commodity prices makes Russia's economy and government spending on healthcare variable, but awareness of healthcare issues, especially among the younger population, and a willingness to spend personal funds on healthcare will drive Russian markets. For the...
    Pharmaceutical Outsourcing Post-Launch : Contract Manufacturing, Biomanufacturing and Sales, 3rd Edition

    Published: January 1, 2009 | Price: $995.00 – $7,000.00

    This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing of prescription drugs and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. A major factor driving the upward trend in the number of manufacturing projects being outsourced is that specialized production, i.e., sterile manufacturing, biopharmaceutical manufacturing and specialized processes, such as chiral chemistry and improvements in catalyst activity, is often not included in the...
    Pharmaceutical Markets in the Middle East (Opportunities, Key Players, Trends in Egypt, Jordan, Israel, Saudi Arabia and UAE)

    Published: November 1, 2008 | Price: $995.00 – $1,990.00

    At present the Middle East region constitutes as small percent of global pharmaceutical sales. However, ever-increasing populations and governmental healthcare reforms are likely to increase demand. These markets will be essential for pharmaceuticals companies exploring new opportunities for growth. Developing regions will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. This Kalorama Information report, Pharmaceutical Markets in the Middle East (Opportunities, Key Players, Trends) takes a thorough look at the...
    Pharmaceutical Markets in Brazil, Russia, India and China ( BRIC nations )

    Published: July 1, 2008 | Price: $500.00 – $7,000.00

    Pharmaceutical markets in Brazil, Russia, India and China rank among the top twenty markets in the world with the potential to move up in ranking rather quickly. (China’s pharmaceutical market, for instance, is expected to show double-digit growth over the next five years.) Developing regions and petro-rich nations will be an integral part of expansion for companies looking to capture a larger portion of the worldwide market. Kalorama's Pharmaceutical Markets in Brazil, Russia, India and China (BRIC nations) takes a...
    Outsourcing in Drug Discovery: The Contract Research (CRO) Market, 3rd Edition

    Published: May 1, 2008 | Price: $3,500.00 – $7,000.00

    2008 has seen no decrease in the opportunities available for outsourcing drug discovery, for a number of reasons. New technologies increase the number of targets and accelerate the identification of active compounds. There is increasing pressure to develop new lead compounds due to the near-term loss of patent protection for many drug product. And there is also pressure to reduce the time spent in drug discovery and to bring drugs to market sooner, as well as the ever-present cost considerations....
    World OTC Pharmaceutical Markets: Self-Medication, Developing and Petro-Based Economies, BTC and Other Growth Trends

    Published: May 1, 2008 | Price: $995.00 – $6,400.00

    Over-the-counter (OTC) drugs are well situated to capitalize on worldwide economic conditions. Customers in the US and in the world under time constraints and tight budgets prefer OTC and are opting to self-medicate where possible. Developing and petro-rich nations are pushing world demand for pharmaceuticals. Pharmacists are favoring OTCs, and are a driving force behind a new class of 'behind the counter' (BTC) drugs. The aging of the population and an increase in medical conditions generally continues to bode well...
    Return of the Rx to OTC Switch – Market Analysis and Product Management Strategies, The

    Published: April 1, 2008 | Price: $500.00 – $3,990.00

    Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life. Kalorama Information's The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the...
    RFID in Pharmaceutical Manufacturing: Cost Saving Strategies for Pharmaceutical Companies and Opportunities for Technology Companies

    Published: March 1, 2008 | Price: $995.00 – $3,990.00

    Pharmaceutical manufacturers are utilizing new RIFD technologies to deal with multiple challenges they face in the manufacturing process. This Kalorama Information report discussions the solutions available, and covers the opportunities available to technology companies to provide services to this sector. Full coverage of the market for RFID technologies in pharmaceutical manufacturing operations is provided, including.   Explanation of RFID Technologies Cost Savings from Implementation Total Market for RFID Technologies in Pharma Manufacturing Market Forecasts Major Companies Involved in RFID and...
    Pharmaceutical Excipients for Oral Formulations, 2nd. Edition

    Published: February 1, 2008 | Price: $995.00 – $7,990.00

    Pharmaceutical excipients are substances, other than the pharmacologically active drug or prodrug, which are included in the manufacturing process or are contained in the finished pharmaceutical product dosage form. Excipients provide enhanced functionality to the pharmaceuticals, aid the innovations in the drug development and help improve patent life as well. Excipients make the products more functional at a lower cost, a benefit much desired by the pharmaceutical industry that is inundated with pressures to reduce costs. All in all, excipients...
    Pharmaceutical Outsourcing Opportunities Post-Launch – Contract Manufacturing and Contract Sales and Marketing, 2nd Edition

    Published: September 1, 2006 | Price: $3,900.00 – $7,800.00

    This report is focused on two expanding pharmaceutical outsourcing markets, contract manufacturing and contract sales and marketing. Both markets represent excellent post launch outsourcing opportunities for companies competing in this fast growing pharmaceutical outsourcing sector. The report contains vital market statistics on three main segments of pharmaceutical contract manufacturing: Biopharmaceutical manufacturing, including monoclonal antibodies (MAbs), complex proteins, peptides, nucleotides, DNA vaccines, and gene therapy. Primary pharmaceutical manufacturing, including non-sterile and sterile active pharmaceutical ingredients (APIs), custom chemicals, certain specialized manufacturing...
    Transgenic Animals and Plants in Pharmaceutical Research and Manufacturing

    Published: January 1, 2006 | Price: $995.00 – $5,990.00

    With the mapping of the human genome and the concomitant explosion of proteomics, a steady stream of biopharmaceuticals have been launched—recombinant therapeutic proteins, monoclonal antibody-based products used for therapeutic or in vivo diagnostic purposes, and nucleic acid-based products. As the rate of regulatory approval for biopharmaceuticals increases, the number of products reaching the market will impose unprecedented demands on the industry’s biomanufacturing capacity. Whether or not this will create a biomanufacturing bottleneck is a hotly debated issue in the industry....
    Pharmaceutical Outsourcing Opportunities Post Launch: Contract Manufacturing, and Sales and Marketing

    Published: July 1, 2004 | Price: $3,500.00 – $7,000.00

    After decades of sustained growth and profitability, the pharmaceutical industry has been positioned as one of the few recession proof industries based on its performance through multiple economical cycles. In recent years, there have been visible strains in the pharmaceutical business. With a downturn in fortunes, many pharmaceutical companies are searching for business solutions to streamline operations and cut costs as they strive to continue generating above-average shareholder returns. Outsourcing has become an integral, ongoing element of pharmaceutical companies’ business...
    Outsourcing in Drug Development – The Contract Research Market from Preclinical to Phase III

    Published: January 1, 2004 | Price: $3,500.00 – $7,000.00

    The cost of drug development has soared during the past ten years compelling pharmaceutical and biotechnology companies to look for new, smarter ways of conducting clinical research. Driven by mounting market pressures, companies are increasingly implementing outsourcing strategies to increase revenues through faster drug development. By decreasing their in-house facilities and staff, and outsourcing more of their R&D functions, pharmaceutical and biotechnology companies are reshaping the drug development services industry. This industry has evolved from providing limited clinical trial services...